Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type

September 1, 2014 updated by: Sun Qing

Study of Abdominal Massage Therapy for Generalized Anxiety Disorder Based on the " Essence Fosters Spirit " Theory

Generalized Anxiety Disorder (GAD) is characterized by the presence of persistent worry or fear of no explicit object and fixed content, or things that might occur in real life,which not corresponds with the realities. Patients with GAD may occur a series of somatic symptoms including muscle tension, backaches, headaches, fatigue, insomnia, restlessness, as well as psychological feelings of anxiety, worry and feeling overwhelmed. And it always brings some type of functional disability or decrease in quality of life. GAD is treated by Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin, Norepinephrine Reuptake Inhibitors(SNRI) and 5-ht1a receptor agonists as regular medication which have the definite effects. But, some adverse reaction of SSRIs or SNRI leads to the compliance of taking medicine of patients with GAD. There is an impressive data suggesting that Abdominal Massage Therapy is effective in decreasing some symptoms of somatic symptoms and psychological feelings.

This study is designed as a parallel group, positive control, non-inferiority study. It will recruit 140 cases of generalized anxiety disorder of deficiency of both heart and spleen type. Both the treatment group and the control group will be randomly assigned 70 cases. Patients in the treatment group will be treated by Abdominal Massage for 6 weeks,and the control group by buspirone . The total study includes 4 views that are respectively before the treatment,after 3 weeks treatment, after the whole treatment , and 3 months after the whole treatment. At all of the 4 views, all participants will be estimated the scores of Hamilton Depression Scale(HAMD) ,self-rating anxiety scale(SAS), and Quality of life assessment scale. At the second, third and the forth views, all participants will be estimated Clinical Global Impression ( CGI). At the first and the third views, all participants will be collected the data of content of hydroxytryptamine(5-HT), Norepinephrine and total cortisol in blood plasma, and of blood stream speed, vascular resistance index and pulsatility index of middle cerebral artery (MCA), anterior cerebral artery(ACA), posterior cerebral artery (PCA) and basilar artery(BA). This study aims to investigate the efficacy of Abdominal Massage Therapy vs. buspirone, and discover the correlation between these scales and these objective indicators.

Study Overview

Status

Unknown

Conditions

Detailed Description

Quality control: The study site and all researchers must comply with the required qualifications. All researchers must be trained before the study. The study will take a number of measures to ensure the recruitment of the required sample size, and compliance of intervention providers and participants.

Study Type

Interventional

Enrollment (Anticipated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Tianjin
      • Tianjin, Tianjin, China, 300193
        • Recruiting
        • The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 50 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Meet criteria for a primary diagnosis of current GAD as demonstrated by a structured clinical interview for Diagnostic and Statistical Manual -IV(DSM-IV);meet a diagnosis of Deficiency of both heart and spleen type.
  • The scores of SAS≥50, 24≥the scores of HAMD ≥15.
  • The symptoms of anxiety have continued not less than 6months.

Exclusion Criteria:

  • major depression, schizophrenia ,bipolar disease other psychotic disorders, drug-dependent persons;
  • patients with severe suicidal tendencies;
  • women in pregnancy or breastfeeding, menstrual or postpartum recovery;
  • suffered from serious illness or impairment of system,such as heart and brain blood vessels, lungs, liver, kidneys and blood system.
  • persons allergic to Buspirone and excipient;
  • persons suffering from epilepsy or hypertension or Glaucoma or myasthenia gravis or leukopenia;
  • persons must be taking monoamine oxidase inhibitors;
  • persons who drink a lot;
  • persons with the local skin lesions in abdomen damage (such as damage, Burns, etc);
  • persons with abdominal visceral tumors, nodules, inflammation, edema, abdominal aortic atherosclerosis;
  • persons without the incompetence or unable to read, write and understand independently;
  • persons whom the researchers believe should not participate in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Abdominal Massage Therapy
Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks
Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
Other Names:
  • Buspirone HCl
Active Comparator: Buspirone
Buspirone by mouth 5mg three times per day for 6week
Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
Other Names:
  • Abdominal Tuina Manipulation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
reductive rate of Hamilton Depression Scale( HAMD reductive rate)
Time Frame: baseline and post- 6week intervention
We will estimate the scores of the Hamilton Depression Scale of participants at baseline and post- 6week intervention,then calculate the HAMD reductive rate according to the following formula:HAMD reductive rate=(scores of HAMD at baseline - scores of HAMD at post- 6week intervention )/ scores of HAMD at baseline×100%
baseline and post- 6week intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Scores of Hamilton Depression Scale(HAMD)
Time Frame: baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
We will estimate the scores of the Hamilton Depression Scale of participants.
baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
Scores of self-rating anxiety scale( SAS)
Time Frame: baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
We will estimate the scores of the self-rating anxiety scale of participants.
baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
Scores of Quality of life assessment scale
Time Frame: baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
We will estimate the scores of the Quality of life assessment scale of participants.
baseline, post- 3week intervention, post- 6week intervention and post-3month after 6- week intervention
Scores of Clinical Global Impression
Time Frame: post- 3week intervention and post- 6week intervention and post-3month after 6- week intervention
We will estimate the scores of Clinical Global Impression.
post- 3week intervention and post- 6week intervention and post-3month after 6- week intervention

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
content of 5-HT in blood plasma
Time Frame: baseline and post- 6week intervention
We will test the content of 5-HT of participants in blood plasma and record the data.
baseline and post- 6week intervention
content of Norepinephrine in blood plasma
Time Frame: baseline and post- 6week intervention
We will test the content of Norepinephrine of participants in blood plasma and record the data.
baseline and post- 6week intervention
content of total cortisol in blood plasma
Time Frame: baseline and post- 6week intervention
We will test the content of total cortisol of participants in blood plasma and record the data.
baseline and post- 6week intervention
blood stream speed of MCA, ACA, PCA and BA
Time Frame: baseline and post- 6week intervention
We will test blood stream speed of MCA, ACA, PCA and BA of patients by Transcranial Doppler and record the data.
baseline and post- 6week intervention
vascular resistance index of MCA, ACA, PCA and BA
Time Frame: baseline and post- 6week intervention
We will test vascular resistance index of MCA, ACA, PCA and BA of patients by Transcranial Doppler and record the data.
baseline and post- 6week intervention
pulsatility index of MCA, ACA, PCA and BA
Time Frame: baseline and post- 6week intervention
We will test pulsatility index of MCA, ACA, PCA and BA of patients by Transcranial Doppler and record the data.
baseline and post- 6week intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2014

Primary Completion (Anticipated)

October 1, 2015

Study Registration Dates

First Submitted

June 23, 2014

First Submitted That Met QC Criteria

July 7, 2014

First Posted (Estimate)

July 10, 2014

Study Record Updates

Last Update Posted (Estimate)

September 3, 2014

Last Update Submitted That Met QC Criteria

September 1, 2014

Last Verified

September 1, 2014

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety Disorders

Clinical Trials on Buspirone

3
Subscribe